SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

High Roller Technologies, Inc. is an evolving and growth-oriented iCasino and entertainment company, which engages in the business of operating an online gaming business offering casino betting games to customers. The firm also offers a wide range of games including many that are available in land-based casinos, such as blackjack, roulette, baccarat, poker, and slot machines. The company was founded by Michael Alexander Cribari and Brandon Christopher Eachus on December 21, 2021 and is headquartered in Las Vegas, NV.

High Roller Technologies Inc.

High Roller Technologies Inc

High Roller Technologies (ROLR) is trending due to its binding partnership with crypto.com/us to launch an event-based prediction markets product in the United States. This news is driving immense excitement and high volatility, with the community speculating on the low-float stock's potential to capitalize on a multi-trillion dollar market. Traders are actively discussing the possibility of a substantial short squeeze and comparing ROLR to previous explosive runs within the online gambling and crypto sectors.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is trending as investor interest intensifies around the critical role of photonics and optical interconnects in next-generation AI and data center infrastructure, following recent industry discussions on co-packaged optics. The community is highly optimistic about POET's patented Optical Interposer technology, viewing it as a game-changer for efficient, high-volume production of optical engines that address bottlenecks in AI computing. Many anticipate imminent news regarding substantial production orders or partnerships with major industry players, despite ongoing market dynamics influenced by upcoming options expiry and perceived price manipulation.

CleanSpark, Inc. is a bitcoin mining technology company, which engages in the management of data centers. Its operations include College Park, Norcross, Washington, Sandersville, Dalton, and Massena. The company was founded by S. Matthew Schultz and Bryan Huber on October 15, 1987 and is headquartered in Henderson, NV.

Cleanspark Inc

Cleanspark (CLSK) is trending due to its notable market momentum, with the community observing its strong performance relative to peers like IREN. A primary talking point among investors revolves around the company's ambitious growth plans and potential share dilution concerns to finance these expansions, despite an overarching bullish sentiment.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin (APP) is experiencing significant volatility, marked by a notable price decline occurring despite recent bullish analyst upgrades that highlight its AI-powered AXON platform and expanding e-commerce advertising initiatives. The community is sharply divided, with many actively buying the dip and attributing the downturn to market manipulation or broader tech sector weakness, while others express concerns about overvaluation and potential further correction. The stock's characteristic swings keep traders engaged, debating its strategic position in the evolving ad-tech landscape.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is generating significant market discussion amid the J.P. Morgan Healthcare Conference, driven by recent advancements in its obesity drug pipeline and the appointment of a Chief Commercial Officer. The community is sharply divided, with many anticipating a major partnership or acquisition given a peer CEO's remarks on substantial M&A spending, while others express skepticism over recent stock performance and the company's presentation style.

New Century Logistics (BVI) Ltd. is a holding company, which is doing business through its subsidiaries, providing air and ocean export and import freight forwarding & logistics services. It offers cargo space, cargo pick up, off-airport air cargo security screening, palletization, preparation of shipping documentation, arrangement of customs clearance to cargo handling at ports and other related services. The company was founded on April 24, 2019 and is headquartered in Hong Kong.

New Century Logistics (BVI) Ltd.

New Century Logistics

New Century Logistics (NCEW) is gaining significant attention following its strategic acquisition announcement in Asia and partnerships for innovative drone-based last-mile delivery. The community is actively discussing its extremely low share float and drawing comparisons to other "Hong Kong low float" stocks that have recently experienced substantial, volatile runs. This focus, coupled with chatter about its high short interest, positions NCEW as a speculative play within the logistics sector.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is trending due to robust preliminary revenue guidance for its flagship MS drug Briumvi, which is surpassing expectations for 2025 and 2026 and positioning it for potential blockbuster status. The community is actively discussing Briumvi's best-in-class profile and market share expansion, especially amidst a competitor's recent regulatory setback, while also expressing frustration over the stock's current valuation and perceived manipulation.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is trending due to significant high-grade rare earth element drilling results from its Tanbreez project, which confirm strategic metals crucial for Western supply chains. The market is also heavily anticipating outcomes from high-level meetings between U.S., Danish, and Greenlandic officials regarding potential U.S. involvement in Greenland's critical mineral resources. This confluence of positive exploration news and strategic geopolitical interest is driving widespread community discussion and strong conviction among investors despite recent volatility.

Unity Software, Inc. engages in the developing video gaming software. It also provides software solutions to create, run and monetize interactive, real-time two-dimensional and three-dimensional content for mobile phones, tablets, consoles, and augmented and virtual reality devices. Its platform is used by developers, artists, and designers to build content for gaming, film, retail, automotive, architecture, engineering, and construction industries. The company was founded by Joachim Ante and David Helgason in 2004 and is headquartered in San Francisco, CA.

Unity Software Inc

Unity is trending amid a wave of analyst upgrades, citing its strengthening mobile advertising platform and the growth potential of new commerce tools within the broader real-time 3D development space. The community is actively discussing a potential breakout beyond previous resistance levels, with many viewing recent dips as buying opportunities while others remain cautious given historical volatility. Optimism is fueled by the performance of its Vector AI platform and strategic partnerships, indicating confidence in its long-term trajectory across gaming, digital twins, and AI applications.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical is trending due to a convergence of compelling clinical advancements and anticipated corporate catalysts. The community is actively discussing strong pancreatic cancer data, a recent FDA filing for recurrent skin cancer, and awaiting Japanese regulatory approval, all contributing to significant market momentum. Investors are keenly focused on the company's presentation at a major healthcare conference this week, alongside widespread anticipation of increased institutional interest.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Notable Two Hundred Day Moving Average Cross - INVA

In trading on Tuesday, shares of Innoviva Inc (Symbol: INVA) crossed below their 200 day moving average of $19.35, changing hands as low as $19.26 per share. Innoviva Inc shares are currently trading...

Synergy Asset Management LLC Invests $1.85 Million in Innoviva, Inc. $INVA

Synergy Asset Management LLC acquired a new position in Innoviva, Inc. (NASDAQ:INVA - Free Report) during the 3rd quarter, according to its most recent filing with the SEC. The fund acquired 101,459...

Innoviva (NASDAQ:INVA) Share Price Crosses Above Two Hundred Day Moving Average - Here's Why

Innoviva (NASDAQ:INVA) Stock Crosses Above Two Hundred Day Moving Average - Here's Why...

Innoviva, Inc. (NASDAQ:INVA) Receives Consensus Rating of "Moderate Buy" from Analysts

Shares of Innoviva, Inc. (NASDAQ:INVA - Get Free Report) have been given an average rating of "Moderate Buy" by the seven research firms that are presently covering the company, Marketbeat Ratings...

FDA Approves Innoviva's NUZOLVENCE, First-in-Class Oral Treatment For Gonorrhea

(RTTNews) - Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (INVA), announced that the U.S. Food and Drug Administration approved NUZOLVENCE (zoliflodacin) for oral suspension, a...

U.S. FDA Approves NUZOLVENCE (zoliflodacin), a First-in-Class, Single-dose, Oral Antibiotic for the Treatment of Uncomplicated Urogenital Gonorrhea in Adults and Adolescents

Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (NASDAQ: INVA), today announced that the U.S. Food and Drug Administration (FDA) has approved NUZOLVENCE (zoliflodacin) for oral...

Innoviva Specialty Therapeutics Announces Publication in The Lancet of Positive Zoliflodacin Phase 3 Data for the Treatment of Uncomplicated Urogenital Gonorrhea

Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc. (NASDAQ: INVA), today announced the publication of positive results from a pivotal Phase 3 trial evaluating its investigational...

State Board of Administration of Florida Retirement System Cuts Stake in Innoviva, Inc. $INVA

State Board of Administration of Florida Retirement System decreased its holdings in Innoviva, Inc. (NASDAQ:INVA - Free Report) by 80.4% in the second quarter, according to its most recent 13F filing...

Innoviva, Inc. $INVA Shares Purchased by Arrowstreet Capital Limited Partnership

Arrowstreet Capital Limited Partnership raised its stake in Innoviva, Inc. (NASDAQ:INVA - Free Report) by 85.3% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The...

Boston Partners Boosts Holdings in Innoviva, Inc. $INVA

Boston Partners lifted its position in shares of Innoviva, Inc. (NASDAQ:INVA - Free Report) by 40.6% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 875,084...

Innoviva, Inc. is engaged in the development, commercialization, and financial management of biopharmaceuticals. Its portfolio includes Relvar Breo Ellipta, which is a once-daily combination medicine consisting of a long-acting beta2 agonist, vilanterol, and an inhaled corticosteroid, fluticasone furoate, and Anoro Ellipta, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, LABA, VI. The company was founded by P. Roy Vagelos, Mathai Mammen, and George M. Whitesides in November 1996 and is headquartered in Burlingame, CA.

Innoviva Inc

Short-Term Volatility, Then Markets Move On

Sustained Risk-Off Until Fed Path Is Clear

Little Impact — Fundamentals Still Rule

Other – Comment Below

Markets pulled back after reports that the DOJ opened a criminal investigation into Federal Reserve Chair Jerome Powell, raising concerns about central bank independence. With rate cuts, inflation, and political pressure all in focus, how do you think this standoff will impact markets in 2026?

How Will the Powell Investigation Impact Markets in 2026?

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	$0.60	--	--	N/A
Q3 '25	$0.46	$1.08	134.78%	BEAT
Q2 '25	$0.50	$0.77	54.30%	BEAT
Q1 '25	$0.29	-$0.74	-351.87%	MISSED
Q4 '24	$0.37	$0.26	-29.73%	MISSED

INVA
Innoviva Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest INVA News

INVAInnoviva Inc